Image

Global Central Nervous System (CNS) Stimulants Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Sep 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Central Nervous System (CNS) Stimulants Market, By Drugs (Phendimetrazine, Phentermine, Methamphetamine, Dextroamphetamine, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Central Nervous System (CNS) Stimulants Market

Central Nervous System (CNS) Stimulants Market Analysis and Size

The global central nervous system (CNS) stimulants market is expected to witness significant growth during the forecast period. Factors such as increasing prevalence of mental illness and presence of specialty centres are protruding factors that drive the global CNS stimulants market. In addition, advances in the treatment options and the presence of well-established healthcare facilities are some of the impacting factors for the growth of eosinophil driven diseases market. COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the global central nervous system (CNS) stimulants market in the forecast period 2022-2029. The expected CAGR of global central nervous system (CNS) stimulants market is tend to be around 6% in the mentioned forecast period. The market was valued at USD 6 billion in 2021, and it would grow upto USD 9.56 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

CNS stimulants are a class of CNS therapeutics that helps in the treatment of depression and other mental illness. The CNS stimulants such as phendimetrazine employ their action by stimulating the activity of brain which fast-track the both physical and mental process and improve the attention and alertness.        

Central Nervous System (CNS) Stimulants Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Phendimetrazine, Phentermine, Methamphetamine, Dextroamphetamine, Others), Indication (Major Depressive Disorder, Anxiety Disorders, Attention Deficit Hyperactivity Disorder, Others), Route of Administration (Oral, Injectable, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Cipla Inc. (India), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Bristol-Myers Squibb Company (U.S.), GSK plc (U.K.), Nielsen Biosciences (U.S.), aurolife (U.S.), Avanthi, Inc (India), Mayne Pharma Group Limited (Australia)

Market Opportunities

  • Increased Clinical Research and Activities
  • Increasing Demand for Retail Pharmacies

Global Central Nervous System (CNS) Stimulants Market Dynamics

Drivers

  • Increase in Elderly Population

According to the WHO, elderly people aged 60 years and above is expected to rise from 900 million in 2015 to 2 billion in 2050. This will lead to surge in incidence of different nervous system related diseases. This boosts the market growth.

  • Increasing Approval of Drugs

Increasing approval of generic products due to patent expiration of key products, such as Copaxone and Invega, has led to an surge in treatment rate, especially in low- and middle-income countries. For instance, the FDA approved two new generic forms of Copaxone, in 2018, which is further anticipated to increase competitive rivalry in the market for central nervous system therapeutics. This boosts the market growth.

Opportunities

  • Increased Clinical Research and Activities

The central nervous system (CNS) stimulants market has faced extensive R&D efforts in the past decade, which have resulted in the lunch of novel drug-delivery systems. The several advancements in the drug-delivery systems are anticipated to rise the adoption of a novel therapy to treat central nervous system diseases. These novel drug-delivery systems overpower the conventional methods due to reduced adverse effects.  

  • Increasing Demand for Retail Pharmacies

Rise in the number of central nervous system (CNS) stimulants being delivered through retail pharmacies and surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.

 Restraints/Challenges

  • Impending Drug Approvals

There are many drugs or injections that await for the approval of the drugs. Receiving approval for the drug from regulatory authorities is a very tedious and challenging task as regulatory authorities such as the U.S. FDA execute substantial and burdensome requirements upon companies involved in the clinical development, marketing, manufacturing, and distribution of drugs.

  • High Cost

The huge expenditure associated with these agents surely hamper the market growth.

This global central nervous system (CNS) stimulants market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global central nervous system (CNS) stimulants market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Central Nervous System (CNS) Stimulants Market

COVID-19 has left global public health crisis that has impacted practically every business. Its long-term consequences are anticipated to influence industry growth during the forecast period. Change of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials. A number of research activities have been performed to understand the relation between the COVID-19 and lysosomal enzyme driven diseases. Additionally, research has been ongoing in which researchers are trying to understand the correlation of mortality in patients due to the COVID-19 and nervous system disorders.

In the post-pandemic era, the biotechnology and pharmaceutical industries are projected to witness a major future growth because of the demand for vaccine and treatment drugs for COVID-19. Thus, this will leave a significant impact on the global central nervous system (CNS) stimulants market.

Global Central Nervous System (CNS) Stimulants Market Scope

The global central nervous system (CNS) stimulants market is segmented on the basis of drug, indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Phendimetrazine
  • Phentermine
  • Methamphetamine
  • Dextroamphetamine
  • Others

Indication

  • Major Depressive Disorder
  • Anxiety Disorders
  • Attention Deficit Hyperactivity Disorder
  • Others

Route of Administration

  • Oral
  • Injectable
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Central Nervous System (CNS) Stimulants Market Regional Analysis/Insights

The global central nervous system (CNS) stimulants market is analysed and market size insights and trends are provided by drug, indication, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global central nervous system (CNS) stimulants market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global central nervous system (CNS) stimulants market throughout the forecast period due to the high demand of diseases specific treatment, rise in depression and substance abuse, presence of refined healthcare expenditure and increased patient awareness level as well as high prevalence of unhealthy lifestyle.

Asia-Pacific dominates the market due to the presence of global marketed players in this region and growing cases of mental illness.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Central Nervous System (CNS) Stimulants Market Share Analysis

The global central nervous system (CNS) stimulants market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global central nervous system (CNS) stimulants market.

Key players operating in the global central nervous system (CNS) stimulants market include:

  • Cipla Inc. (India)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Aurobindo Pharma (India)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc (U.K.)
  • Nielsen Biosciences (U.S.)
  • aurolife (U.S.)
  • Avanthi, Inc (India)
  • Mayne Pharma Group Limited (Australia)


SKU-
Why Choose Us


Frequently Asked Questions

The Central Nervous System (CNS) Stimulants Market is expected to grow at a CAGR of 6% during the forecast period by 2029.
The future market value of the Central Nervous System (CNS) Stimulants Market reach $9.56 Billion by 2029.
The key players in the Central Nervous System (CNS) Stimulants Market are Cipla Inc., Mylan N.V, Teva Pharmaceutical Industries Ltd, Sanofi, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma, Bristol-Myers Squibb Company, GSK plc, Nielsen Biosciences, aurolife, Avanthi Inc, Mayne Pharma Group Limited.
The countries covered in the Central Nervous System (CNS) Stimulants Market are the U.S., Canada, and Mexico in North America, Germany, France, the U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, etc.